Fokke G. Terpstra
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Fokke G. Terpstra has a total of 27 co-authors. Here are the top co-authors by number of shared publications:
H. Schuitemaker
2 shared publicationsA. H. L. Koenderman
Sanquin, Division of Plasma Products, Amsterdam, the Netherlands
1 shared publicationA.B. van 'T Wout
1 shared publicationA.B. van ’t Wout
1 shared publicationA.E. van Den Blink
1 shared publicationA.G.C. Boots
1 shared publication
Latest Publications
- 20 November 2007
- Published by Wiley in Transfusion
- Vol. 48 (2) , 304-313
Potential and limitation of UVC irradiation for the inactivation of pathogens in platelet concentrates
BACKGROUND: Pathogen contamination, causing transfusion‐transmitted diseases, is an ongoing concern in transfusion of cellular blood products. In this explorative study, the pathogen‐inactivating capacity of UVC irradiation in platelet (PLT) concentrates was investigated. The dose dependencies of inactivation of several viruses and bacteria were compared with the effect on PLT quality.STUDY DESIGN AND METHODS: The potential of UVC irradiation was studied with a range of lipid‐enveloped (LE) and non–lipid‐enveloped viruses (NLE) and bacteria. LE viruses were bovine viral diarrhea virus (BVDV), human immunodeficiency virus (HIV), pseudorabies virus (PRV), transmissible gastroenteritis virus (TGEV), and vesicular stomatitis virus (VSV). NLE viruses were canine parvovirus (CPV) and simian virus 40 (SV40). Bacteria were Staphylococcus epidermidis, Staphylococcus aureus, Escherichia coli, and Bacillus cereus. After spiking and irradiation, samples were tested for residual infectivity and reduction factors (RFs) were calculated. Furthermore, the effect of UVC irradiation on PLT quality was determined by measuring in vitro quality variables.RESULTS: A UVC dose of 500 J per m2 resulted in acceptable PLT quality (as measured by pH, lactate production, CD62P expression, and exposure of phosphatidylserine) and high RFs (>4 log) for CPV, TGEV, VSV, S. epidermidis, S. aureus, and E. coli. Intermediate RFs (approx. 3 log) were observed for BVDV, PRV, and B. cereus. Low RFs (approx. 1 log) were found for HIV and SV40. No differences in virus reduction were observed between cell‐free and cell‐associated virus.CONCLUSION: UVC irradiation is a promising pathogen‐reducing technique in PLT concentrates, inactivating bacteria, and a broad range of viruses (with the exception of HIV) under conditions that have limited effects on PLT quality. Further optimization of the UVC procedure, however, is necessary to deal with blood‐borne viruses like HIV.
- 20 November 2007
- Published by Wiley in Transfusion
- Vol. 48 (2) , 304-313
Potential and limitation of UVC irradiation for the inactivation of pathogens in platelet concentrates
BACKGROUND: Pathogen contamination, causing transfusion‐transmitted diseases, is an ongoing concern in transfusion of cellular blood products. In this explorative study, the pathogen‐inactivating capacity of UVC irradiation in platelet (PLT) concentrates was investigated. The dose dependencies of inactivation of several viruses and bacteria were compared with the effect on PLT quality.STUDY DESIGN AND METHODS: The potential of UVC irradiation was studied with a range of lipid‐enveloped (LE) and non–lipid‐enveloped viruses (NLE) and bacteria. LE viruses were bovine viral diarrhea virus (BVDV), human immunodeficiency virus (HIV), pseudorabies virus (PRV), transmissible gastroenteritis virus (TGEV), and vesicular stomatitis virus (VSV). NLE viruses were canine parvovirus (CPV) and simian virus 40 (SV40). Bacteria were Staphylococcus epidermidis, Staphylococcus aureus, Escherichia coli, and Bacillus cereus. After spiking and irradiation, samples were tested for residual infectivity and reduction factors (RFs) were calculated. Furthermore, the effect of UVC irradiation on PLT quality was determined by measuring in vitro quality variables.RESULTS: A UVC dose of 500 J per m2 resulted in acceptable PLT quality (as measured by pH, lactate production, CD62P expression, and exposure of phosphatidylserine) and high RFs (>4 log) for CPV, TGEV, VSV, S. epidermidis, S. aureus, and E. coli. Intermediate RFs (approx. 3 log) were observed for BVDV, PRV, and B. cereus. Low RFs (approx. 1 log) were found for HIV and SV40. No differences in virus reduction were observed between cell‐free and cell‐associated virus.CONCLUSION: UVC irradiation is a promising pathogen‐reducing technique in PLT concentrates, inactivating bacteria, and a broad range of viruses (with the exception of HIV) under conditions that have limited effects on PLT quality. Further optimization of the UVC procedure, however, is necessary to deal with blood‐borne viruses like HIV.
- 1 August 2007
- Published by Elsevier in Journal of Hospital Infection
- Vol. 66 (4) , 332-338
Resistance of surface-dried virus to common disinfection procedures
- 1 August 2007
- Published by Elsevier in Journal of Hospital Infection
- Vol. 66 (4) , 332-338
Resistance of surface-dried virus to common disinfection procedures
- 1 June 2007
- Published by Elsevier in Biologicals
- Vol. 35 (3) , 173-181
Viral safety of C1-inhibitor NF
- 1 June 2007
- Published by Elsevier in Biologicals
- Vol. 35 (3) , 173-181
Viral safety of C1-inhibitor NF
- 6 December 2005
- Published by Wiley in Vox Sanguinis
- Vol. 90 (1) , 21-32
Viral safety of Nanogam®, a new 15 nm‐filtered liquid immunoglobulin product
Background and Objectives Producers of plasma derivatives continuously improve the viral safety of their products by, for example, introducing additional virus‐reducing steps into the manufacturing process. Here we present virus‐elimination studies undertaken for a number of steps employed in a new manufacturing process for liquid intravenous immunoglobulin (Nanogam®) that comprises two specific virus‐reducing steps: a 15‐nm filtration step combined with pepsin treatment at pH 4·4 (pH 4·4/15NF); and solvent–detergent (SD) treatment. The manufacturing process also includes precipitation of Cohn fraction III and viral neutralization, which contribute to the total virus‐reducing capacity of the manufacturing process. In addition, the mechanism and robustness of the virus‐reducing steps were studied.Materials and Methods Selected process steps were studied with spiking experiments using a range of lipid enveloped (LE) and non‐lipid‐enveloped (NLE) viruses. The LE viruses used were bovine viral diarrhoea virus (BVDV), human immunodeficiency virus (HIV) and pseudorabies virus (PRV); the NLE viruses used were parvovirus B19 (B19), canine parvovirus (CPV) and encephalomyocarditis virus (EMC). After spiking, samples were collected and tested for residual infectivity, and the reduction factors were calculated. For B19, however, removal of B19 DNA was measured, not residual infectivity. To reveal the contribution of viral neutralization, bovine parvovirus (BPV) and hepatitis A virus (HAV) were used.Results For the pH 4·4/15NF step, complete reduction (> 6 log10) was demonstrated for all viruses, including B19, but not for CPV (> 3·4 but ≤ 4·2 log10). Robustness studies of the pH 4·4/15NF step with CPV showed that pH was the dominant process parameter. SD treatment for 10 min resulted in complete inactivation (> 6 log10) of all LE viruses tested. Precipitation of Cohn fraction III resulted in the significant removal (3–4 log10) of both LE and NLE viruses. Virus‐neutralization assays of final product revealed significant reduction (≥ 3 log10) of both BPV and HAV.Conclusions The manufacturing process of Nanogam® comprises two effective steps for the reduction of LE viruses and one for NLE viruses. In addition, the precipitation of Cohn fraction III and the presence of neutralizing antibodies contribute to the total virus‐reducing capacity of Nanogam®. The overall virus‐reducing capacity was > 15 log10 for LE viruses. For the NLE viruses B19, CPV and EMC, the overall virus‐reducing capacities were > 10, > 7 and > 9 log10, respectively. Including the contribution of immune neutralization, the overall virus‐reducing capacity for B19 and HAV is estimated to be > 10 log10.
- 6 December 2005
- Published by Wiley in Vox Sanguinis
- Vol. 90 (1) , 21-32
Viral safety of Nanogam®, a new 15 nm‐filtered liquid immunoglobulin product
Background and Objectives Producers of plasma derivatives continuously improve the viral safety of their products by, for example, introducing additional virus‐reducing steps into the manufacturing process. Here we present virus‐elimination studies undertaken for a number of steps employed in a new manufacturing process for liquid intravenous immunoglobulin (Nanogam®) that comprises two specific virus‐reducing steps: a 15‐nm filtration step combined with pepsin treatment at pH 4·4 (pH 4·4/15NF); and solvent–detergent (SD) treatment. The manufacturing process also includes precipitation of Cohn fraction III and viral neutralization, which contribute to the total virus‐reducing capacity of the manufacturing process. In addition, the mechanism and robustness of the virus‐reducing steps were studied.Materials and Methods Selected process steps were studied with spiking experiments using a range of lipid enveloped (LE) and non‐lipid‐enveloped (NLE) viruses. The LE viruses used were bovine viral diarrhoea virus (BVDV), human immunodeficiency virus (HIV) and pseudorabies virus (PRV); the NLE viruses used were parvovirus B19 (B19), canine parvovirus (CPV) and encephalomyocarditis virus (EMC). After spiking, samples were collected and tested for residual infectivity, and the reduction factors were calculated. For B19, however, removal of B19 DNA was measured, not residual infectivity. To reveal the contribution of viral neutralization, bovine parvovirus (BPV) and hepatitis A virus (HAV) were used.Results For the pH 4·4/15NF step, complete reduction (> 6 log10) was demonstrated for all viruses, including B19, but not for CPV (> 3·4 but ≤ 4·2 log10). Robustness studies of the pH 4·4/15NF step with CPV showed that pH was the dominant process parameter. SD treatment for 10 min resulted in complete inactivation (> 6 log10) of all LE viruses tested. Precipitation of Cohn fraction III resulted in the significant removal (3–4 log10) of both LE and NLE viruses. Virus‐neutralization assays of final product revealed significant reduction (≥ 3 log10) of both BPV and HAV.Conclusions The manufacturing process of Nanogam® comprises two effective steps for the reduction of LE viruses and one for NLE viruses. In addition, the precipitation of Cohn fraction III and the presence of neutralizing antibodies contribute to the total virus‐reducing capacity of Nanogam®. The overall virus‐reducing capacity was > 15 log10 for LE viruses. For the NLE viruses B19, CPV and EMC, the overall virus‐reducing capacities were > 10, > 7 and > 9 log10, respectively. Including the contribution of immune neutralization, the overall virus‐reducing capacity for B19 and HAV is estimated to be > 10 log10.